Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02169934 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Metabolism and Excretion of [14C]-TRV130 in Healthy Male Subjects
A Phase 1 study, sponsored by Trevena.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02169934 is a Phase 1 study that has completed, run by Trevena. The registered enrollment target is 6 participants.
The verdict
NCT02169934, a Phase 1 study, has completed, sponsored by Trevena.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the routes of excretion for TRV130 and it's metabolites, and to determine and characterize, structurally, the metabolites present in plasma, urine, and feces in healthy male subjects.
Interventions
- DRUG Radiolabeled TRV130
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02169934
The ClinicalTrials.gov registry entry for NCT02169934 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trevena, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Radiolabeled TRV130 is the first listed.
NCT02169934 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02169934 about?
NCT02169934 is a clinical study titled "A Study to Investigate the Metabolism and Excretion of [14C]-TRV130 in Healthy Male Subjects". The purpose of this study is to determine the routes of excretion for TRV130 and it's metabolites, and to determine and characterize, structurally, the metabolites present in plasma, urine, and feces in healthy male subjects.
What is the current status of trial NCT02169934?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2014-06. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02169934?
The interventions under investigation include: Radiolabeled TRV130 (DRUG).
Who is sponsoring clinical trial NCT02169934?
This trial is sponsored by Trevena, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.